Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Koch, Raphael, Christie, Amanda L., Crombie, Jennifer L., Palmer, Adam C., Plana, Deborah, Shigemori, Kay, Morrow, Sara N., Van Scoyk, Alexandria, Wu, Wenchao, Brem, Elizabeth A., Secrist, J. Paul, Drew, Lisa, Schuller, Alwin G., Cidado, Justin, Letai, Anthony, Weinstock, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367646/
https://ncbi.nlm.nih.gov/pubmed/30498064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-865527
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados